170 related articles for article (PubMed ID: 36990009)
1. Mechanisms of theaflavins against gout and strategies for improving the bioavailability.
Chen J; Zheng Y; Gong S; Zheng Z; Hu J; Ma L; Li X; Yu H
Phytomedicine; 2023 Jun; 114():154782. PubMed ID: 36990009
[TBL] [Abstract][Full Text] [Related]
2. GLUT9 influences uric acid concentration in patients with Lesch-Nyhan disease.
Torres RJ; Puig JG
Int J Rheum Dis; 2018 Jun; 21(6):1270-1276. PubMed ID: 29879316
[TBL] [Abstract][Full Text] [Related]
3. The molecular insight into the antihyperuricemic and renoprotective effect of Shuang Qi gout capsule in mice.
Kodithuwakku ND; Feng YD; Zhang YY; Pan M; Fang WR; Li YM
J Ethnopharmacol; 2015 Apr; 163():278-89. PubMed ID: 25614106
[TBL] [Abstract][Full Text] [Related]
4. Genetics of hyperuricemia and gout: implications for the present and future.
George RL; Keenan RT
Curr Rheumatol Rep; 2013 Feb; 15(2):309. PubMed ID: 23307580
[TBL] [Abstract][Full Text] [Related]
5. Berberrubine attenuates potassium oxonate- and hypoxanthine-induced hyperuricemia by regulating urate transporters and JAK2/STAT3 signaling pathway.
Lin G; Yu Q; Xu L; Huang Z; Mai L; Jiang L; Su Z; Xie J; Li Y; Liu Y; Lin Z; Chen J
Eur J Pharmacol; 2021 Dec; 912():174592. PubMed ID: 34699754
[TBL] [Abstract][Full Text] [Related]
6. The genetics of hyperuricaemia and gout.
Reginato AM; Mount DB; Yang I; Choi HK
Nat Rev Rheumatol; 2012 Oct; 8(10):610-21. PubMed ID: 22945592
[TBL] [Abstract][Full Text] [Related]
7. Crystal ball gazing: new therapeutic targets for hyperuricaemia and gout.
Dalbeth N; Merriman T
Rheumatology (Oxford); 2009 Mar; 48(3):222-6. PubMed ID: 19109320
[TBL] [Abstract][Full Text] [Related]
8. Novel uricosurics.
Bardin T; Richette P
Rheumatology (Oxford); 2018 Jan; 57(suppl_1):i42-i46. PubMed ID: 29272511
[TBL] [Abstract][Full Text] [Related]
9. Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney.
Miner JN; Tan PK; Hyndman D; Liu S; Iverson C; Nanavati P; Hagerty DT; Manhard K; Shen Z; Girardet JL; Yeh LT; Terkeltaub R; Quart B
Arthritis Res Ther; 2016 Oct; 18(1):214. PubMed ID: 27716403
[TBL] [Abstract][Full Text] [Related]
10. ABCG2 as a therapeutic target candidate for gout.
Fujita K; Ichida K
Expert Opin Ther Targets; 2018 Feb; 22(2):123-129. PubMed ID: 29264928
[TBL] [Abstract][Full Text] [Related]
11. Siwu decoction attenuates oxonate-induced hyperuricemia and kidney inflammation in mice.
Wang R; Ma CH; Zhou F; Kong LD
Chin J Nat Med; 2016 Jul; 14(7):499-507. PubMed ID: 27507200
[TBL] [Abstract][Full Text] [Related]
12. Novel urate transporter 1 (URAT1) inhibitors: a review of recent patent literature (2020-present).
Shi X; Zhao T; da Silva-Júnior EF; Zhang J; Xu S; Gao S; Liu X; Zhan P
Expert Opin Ther Pat; 2022 Dec; 32(12):1175-1184. PubMed ID: 36625031
[TBL] [Abstract][Full Text] [Related]
13. Discovery of novel verinurad analogs as dual inhibitors of URAT1 and GLUT9 with improved Druggability for the treatment of hyperuricemia.
Zhao Z; Liu J; Kuang P; Luo J; Surineni G; Cen X; Wu T; Cao Y; Zhou P; Pang J; Zhang Q; Chen J
Eur J Med Chem; 2022 Feb; 229():114092. PubMed ID: 34998055
[TBL] [Abstract][Full Text] [Related]
14. Limitations of the Current Standards of Care for Treating Gout and Crystal Deposition in the Primary Care Setting: A Review.
Keenan RT
Clin Ther; 2017 Feb; 39(2):430-441. PubMed ID: 28089200
[TBL] [Abstract][Full Text] [Related]
15. Recent advances in renal urate transport: characterization of candidate transporters indicated by genome-wide association studies.
Anzai N; Jutabha P; Amonpatumrat-Takahashi S; Sakurai H
Clin Exp Nephrol; 2012 Feb; 16(1):89-95. PubMed ID: 22038265
[TBL] [Abstract][Full Text] [Related]
16. Saponins extracted from Dioscorea collettii rhizomes regulate the expression of urate transporters in chronic hyperuricemia rats.
Zhu L; Dong Y; Na S; Han R; Wei C; Chen G
Biomed Pharmacother; 2017 Sep; 93():88-94. PubMed ID: 28624426
[TBL] [Abstract][Full Text] [Related]
17. A new perspective on the pharmacoeconomics of colchicine.
Wertheimer AI; Davis MW; Lauterio TJ
Curr Med Res Opin; 2011 May; 27(5):931-7. PubMed ID: 21370937
[TBL] [Abstract][Full Text] [Related]
18. Gout in 2006: the perfect storm.
Terkeltaub R
Bull NYU Hosp Jt Dis; 2006; 64(1-2):82-6. PubMed ID: 17121496
[TBL] [Abstract][Full Text] [Related]
19. Recent approaches to gout drug discovery: an update.
Otani N; Ouchi M; Kudo H; Tsuruoka S; Hisatome I; Anzai N
Expert Opin Drug Discov; 2020 Aug; 15(8):943-954. PubMed ID: 32329387
[TBL] [Abstract][Full Text] [Related]
20. Human sodium phosphate transporter 4 (hNPT4/SLC17A3) as a common renal secretory pathway for drugs and urate.
Jutabha P; Anzai N; Kitamura K; Taniguchi A; Kaneko S; Yan K; Yamada H; Shimada H; Kimura T; Katada T; Fukutomi T; Tomita K; Urano W; Yamanaka H; Seki G; Fujita T; Moriyama Y; Yamada A; Uchida S; Wempe MF; Endou H; Sakurai H
J Biol Chem; 2010 Nov; 285(45):35123-32. PubMed ID: 20810651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
